MAHON PAUL A sold $4.4M of UTHR
MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $533.69 ($527.60–$536.85, $4.43M total) across 8 trades on 2026-07-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price range, and that it was executed under a pre-arranged Rule 10b5-1 plan on 2026-07-16.
Market read
Traders may monitor insider activity for sentiment, but 10b5-1 typically lowers the probability that the sale is information-driven.
What to watch
The filing does not indicate whether other insiders or the company had concurrent news; without follow-on context, the signal is mostly about positioning and sentiment.
Background
The article is a SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics EVP and General Counsel Paul A. Mahon sold 8,300 shares on 2026-07-16 for about $4.43M under a 10b5-1 plan.
Near-term price impact is likely limited; any reaction would be more sentiment-driven than fundamental.
Form 4 provides a concrete transaction size and timing, but the presence of a 10b5-1 plan suggests the trades were scheduled rather than information-driven.
Market effects
No direct sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be routine liquidity management, so the trade may not reflect bearish expectations.
Key entities
- issuerUNITED THERAPEUTICS Corp
Subject of the Form 4 insider transaction disclosure.
- insiderMAHON PAUL A
EVP & General Counsel who sold shares under a 10b5-1 plan.
